• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [224 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support for diabetes, heart disease and HIV/AIDS: a review of the clinical effectiveness, cost-effectiveness, and guidelines
2013 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013 National Institute for Health and Care Excellence (NICE) Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy. NICE interventional procedures guidance 439
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rilpivirine (Edurant®)
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Nevirapine (Viramune®)
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Emtricitabine/rilpivirine/tenofovir (Eviplera®)
2012 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Darunavir (Prezista®)
2012 Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in special populations: a review of the clinical evidence and guidelines
2012 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [HIV screening in the general population]
2012 HAYES, Inc. Recombinant growth hormone treatment for AIDS/HIV-associated wasting and lipodystrophy
2012 Health Information and Quality Authority (HIQA) Economic evaluation of repeat universal antenatal screening for HIV in the third trimester of pregnancy
2012 Agency for Healthcare Research and Quality (AHRQ) Screening for HIV in pregnant women: systematic review to update the U.S. Preventive Services Task Force Recommendation.
2012 Agency for Healthcare Research and Quality (AHRQ) Screening for HIV: systematic review to update the U.S. Preventive Services Task Force Recommendation
2012 Medical Services Advisory Committee (MSAC) Pathology test to determine if a patient has been infected with CCR5 tropic HIV-1 for access to maraviroc
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rilpivirine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Emtricitabine/rilpivirine/tenofovir disoproxil - Addendum to the benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2011 NIHR Health Technology Assessment programme Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation
2011 Health Information and Quality Authority (HIQA) A health technology assessment of prion filtration of red cell concentrates to reduce the risk of variant Creutzfeldt-Jakob disease transmission in Ireland
2011 HAYES, Inc. Rapid antibody tests for HIV screening
2011 HAYES, Inc. Trofile™ HIV tropism assay
2011 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Darunavir (Prezista®)
2011 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (Nivestim®)
2011 Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of active immunotherapy in HIV-infected adults. Therapeutic vaccines against HIV.]
2011 Norwegian Knowledge Centre for the Health Services (NOKC) [Motivational interviewing for HIV-related behaviors among men who have sex with men]
2010 NIHR Health Technology Assessment programme Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer
2010 Medical Advisory Secretariat (MAS) Solid organ transplantation for End Stage Organ Failure (ESOF) in persons with HIV
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Atazanavir (Reyataz®) capsules
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) capsules
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®) oral solution
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (TevaGrastim®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (Zarzio®)
2010 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretrovirals for the treatment of HIV-1 infection in adults
2009 Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [HIV infection detection quick test]
2009 Medical Services Advisory Committee (MSAC) Genotypic resistance testing of antiretrovirals in HIV
2009 Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Permanent and semi permanent dermal fillers
2009 NIHR Health Technology Assessment programme Non-occupational post-exposure prophylaxis for HIV
2009 NIHR Health Technology Assessment programme Non-occupational post-exposure prophylaxis for HIV: a systematic review
2009 Health Intervention and Technology Assessment Program (HITAP) The potential of provider-initiated voluntary HIV counseling and testing at health care settings in Thailand
2009 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Physical disease in schizophrenia: systematic review and analysis of hospital records]
2009 Canadian Agency for Drugs and Technologies in Health (CADTH) Point-of-care HIV testing: a review of the clinical and cost-effectiveness and diagnostic accuracy
2009 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Darunavir (Prezista®) for the treatment of HIV-1 infected, treatment-naïve adults in combination with other antiretroviral medicinal products
2009 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Filgrastim (Ratiograstim®) for the treatment of neutropenia
2009 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Etravirine (Intelence®) for the treatment of HIV-1 infected, antiretroviral treatment-experienced adults in combination with a boosted protease inhibitor and other antiretroviral medicinal products
2009 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Maraviroc (Celsentri®) for treatment-experienced adults infected only with CCR5-tropic HIV-1
2009 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) for the treatment of HIV-1 infection in adults
2008 Agency for Healthcare Research and Quality (AHRQ) Management of chronic hepatitis B
2008 Canadian Agency for Drugs and Technologies in Health (CADTH) Octreotide for endocrine, oncologic, and gastrointestinal disorders: systematic review and budget impact analysis
2008 HAYES, Inc. HLA-B*5701 screening for abacavir (ziagen) hypersensitivity in HIV patients
2008 Health Intervention and Technology Assessment Program (HITAP) Identifying information regarding effectiveness and cost-effectiveness of policy and strategies reorientation to mitigate the impact of HIV/AIDS in Thailand
2008 Committee for New Health Technology Assessment (CNHTA) [HIV antibody test (including oral fluid)]
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Atazanavir (Reyataz®) for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-experienced patients
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Atazanavir (Reyataz®) for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-naive patients
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Abacavir 600mg/lamivudine 300mg (Kivexa®) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age
2007 Haute Autorite de sante (HAS) Detection of HIV RNA and DNA in sperm fractions
2007 Agency for Healthcare Research and Quality (AHRQ) Antiretroviral (ARV) drug resistance in the developing world
2007 Medical Advisory Secretariat (MAS) Anal dysplasia screening: an evidence-based analysis
2007 Adelaide Health Technology Assessment (AHTA) OraSure HIV point of care testing
2007 HAYES, Inc. Rapid antibody testing for HIV
2007 Basque Office for Health Technology Assessment (OSTEBA) [Sexually transmitted diseases. Situation in the Basque Autonomous Community. Effectiveness of preventive measures]
2007 Canadian Agency for Drugs and Technologies in Health (CADTH) Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1
2007 HAYES, Inc. Erythropoiesis-stimulating agents (ESAs) for interferon/ribavirin-induced anemia in HIV-negative patients with hepatitis C
2007 Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) BRATS 03: Nucleic acids amplification tests (NAT) and other strategies for the detection of HIV-1 and HCV viruses in the selection of donated blood
2007 Agency for Healthcare Research and Quality (AHRQ) Screening for human immunodeficiency virus: focused update of a 2005 systematic evidence review for the U.S. Preventive Services Task Force
2007 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Darunavir (Prezista®)
2007 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tipranavir (Aptivus®)
2007 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Emtricitabine (Emtriva®)
2007 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Emtricitabine/tenofovir DF (Truvada®)
2006 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccines for HIV
2006 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Vaccine for herpes simplex
2006 Institute for Clinical Effectiveness and Health Policy (IECS) Main clinical uses of liposomal doxorubicin
2006 Institute for Clinical Effectiveness and Health Policy (IECS) Etanercept, infliximab and adalimumab for the treatment of rheumatoid arthritis
2006 NIHR Health Technology Assessment programme Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation
2006 HAYES, Inc. Intravenous immunoglobulin for children with HIV infection
2006 Institute for Clinical Effectiveness and Health Policy (IECS) Hyperbaric oxygen therapy: diagnostic usefulness and indications
2006 NIHR Horizon Scanning Centre (NIHR HSC) Maraviroc (UK 427857) for resistant HIV: horizon scanning technology briefing
2006 Institute for Clinical Effectiveness and Health Policy (IECS) Soft tissue augmentation for HIV patients with lipodystrophy syndrome
2006 NIHR Horizon Scanning Centre (NIHR HSC) MK-0518 for infection with HIV: horizon scanning technology briefing
2005 Agency for Healthcare Research and Quality (AHRQ) Screening for human immunodeficiency virus in adolescents and adults
2005 Agency for Healthcare Research and Quality (AHRQ) Screening for human immunodeficiency virus in pregnant women: evidence synthesis
2005 HAYES, Inc. Intravenous immunoglobulin for acquired immune deficiency syndrome (AIDS) in adults
2005 Malaysian Health Technology Assessment Unit (MHTAU) Ozone therapy
2004 Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Needs in health and the use of health services in the immigrant population in Catalonia. Exhaustive revision of the scientific literature
2004 West Midlands Health Technology Assessment Collaboration (WMHTAC) Behavioural interventions to reduce the risk of sexually transmitted infections in genitourinary medicine clinic patients: a systematic review
2004 Institute for Clinical Effectiveness and Health Policy (IECS) Antiretroviral resistance testing in HIV patients
2004 Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Sperm-washing in HIV-serodiscordant couples for use in assisted reproduction techniques
2004 ECRI Human immunodeficiency virus (HIV) drug-resistance testing to guide choice of antiretroviral regimen
2004 Adelaide Health Technology Assessment (AHTA) Uni-Gold (TM) Recombigen (R) HIV test to detect antibodies to HIV-1 in the plasma and whole blood of individuals at risk of HIV infection
2003 Alberta Heritage Foundation for Medical Research (AHFMR) Hyperbaric oxygen therapy - recent findings on evidence for its effectiveness. Update
2003 Agency for Healthcare Research and Quality (AHRQ) Criteria for determining disability in infants and children: short stature
2003 Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Enfuvirtide, a new treatment for HIV infection
2003 Hannover Medical School, Medizinische Hochschule Hannover (MHH) Evaluation of genotypic and phenotypic definition of resistance in the treatment of patients infected by HIV - medical efficacy and economic efficiency
2003 German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) Evaluation of the genotypic and phenotypic definition of resistance in the treatment of patients infected by HIV - Medical efficacy and economic efficiency
2002 NIHR Horizon Scanning Centre (NIHR HSC) T-20 for HIV - horizon scanning review
2002 Agency for Healthcare Research and Quality (AHRQ) Management of chronic hepatitis C
2002 Technology Assessment Unit of the McGill University Health Centre (MUHC) Should the McGill University Health Center replace the Jelco/Cathlon catheter by the ProtectIVPlus catheter for intravenous infusions?
2002 HAYES, Inc. Recombinant growth hormone treatment for AIDS/HIV-associated wasting and lipodystrophy
2002 ECRI Interleukin-2 (aldesleukin) for the treatment of HIV infection
2001 Medical Services Advisory Committee (MSAC) Hyperbaric oxygen therapy